HLS Therapeutics (OTCMKTS:HLTRF – Get Rating) had its target price cut by research analysts at Stifel Nicolaus from C$26.00 to C$18.00 in a report issued on Friday, The Fly reports.
Separately, Raymond James cut shares of HLS Therapeutics from an “outperform” rating to a “market perform” rating in a report on Friday.
HLS Therapeutics Trading Down 3.8 %
OTCMKTS HLTRF opened at $5.11 on Friday. HLS Therapeutics has a twelve month low of $4.96 and a twelve month high of $12.01. The firm’s 50 day moving average price is $6.83 and its two-hundred day moving average price is $7.07.
HLS Therapeutics Company Profile
HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular (CV) markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsules; and PERSERIS, an injectable risperidone product for the treatment of schizophrenia.
Read More
- Get a free copy of the StockNews.com research report on HLS Therapeutics (HLTRF)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for HLS Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HLS Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
